Biotech patent owners may be missing a trick by ignoring the ITC
The rise of biosimilar disputes, and the growing importance of life sciences innovations outside human therapeutics, could see an upswing in Section 337 actions
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.